Clinical trial of clonidine hydrochloride as an antisecretory agent in cholera
Clonidine hydrochloride (an α2-adrenoceptor agonist) was tested for antisecretory effects in patients with cholera in a randomized controlled trial. Nineteen adults with diarrhea due to Vibrio cholerae were treated with clonidine (0.9 mg/24 h orally for 72 h) and 18 served as controls. During the fi...
Gespeichert in:
Veröffentlicht in: | Gastroenterology (New York, N.Y. 1943) N.Y. 1943), 1989-08, Vol.97 (2), p.321-325 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 325 |
---|---|
container_issue | 2 |
container_start_page | 321 |
container_title | Gastroenterology (New York, N.Y. 1943) |
container_volume | 97 |
creator | Rabbani, G.H. Butler, Thomas Patte, Didier Abud, Rodney L. |
description | Clonidine hydrochloride (an α2-adrenoceptor agonist) was tested for antisecretory effects in patients with cholera in a randomized controlled trial. Nineteen adults with diarrhea due to Vibrio cholerae were treated with clonidine (0.9 mg/24 h orally for 72 h) and 18 served as controls. During the first 24 h of treatment and for 24 h afterwards, the mean ± SD concentrations of sodium (in millimoles per liter) in the stools of clonidine-treated patients were 120.6 ± 10.9 and 112.3 ± 11.9, which were significantly lower than 135.5 ± 17.1 and 125.0 ± 16.4 in the controls (p < 0.01). Stool chloride concentrations (in millimoles per liter) were also significantly less in the clonidine group during the same periods: 82.1 ± 16.8 and 62.4 ± 19.4 vs. 92.1 ± 18.3 and 78.0 ± 23.0, respectively (p < 0.05). Concentrations of potassium but not bicarbonate were also significantly reduced in the stools of clonidine-treated patients (p < 0.05). However, there were no significant differences in the mean ± SD stool volumes (in liters) between the clonidine and the control group in any of the six 12-h periods after treatment or in the cumulative volumes in 72 h (24.2 ± 10.6 and 22.9 ± 8.3, respectively). We conclude that clonidine causes modest reduction of stool electrolyte loss but does not significantly reduce fecal fluid loss in patients with cholera. |
doi_str_mv | 10.1016/0016-5085(89)90067-X |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79085863</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>001650858990067X</els_id><sourcerecordid>79085863</sourcerecordid><originalsourceid>FETCH-LOGICAL-c433t-5d700579cca54c0e35a8f2ee8128b5f0d96cf6fc117f6faec5c63d08cf929d693</originalsourceid><addsrcrecordid>eNp9kEFrGzEQhUVocZw0_yCFvTSkh20lraWVLoFgkqZg2ksLvgllNKoV1lIirQv-95Fjk9wCw8zhvXnMfIScM_qNUSa_09paQZW4VPqrplT27fKITJngqq0a_0Cmr5ZjclLKA6VUd4pNyIRL2UlGp-TXfAgxgB2aMYfak29gSDG4ELFZbV1OsBpSDg4bWxoba42hIGQcU9429h_GsQmxgVUaMNtP5KO3Q8Gzwzwlf29v_szv2sXvHz_n14sWZl03tsL1lIpeA1gxA4qdsMpzRMW4uheeOi3BSw-M9XVYBAGyc1SB11w7qbtTcrHPfczpaYNlNOtQAIfBRkybYnpdn1ayq8bZ3gg5lZLRm8cc1jZvDaNmh9HsGJkdI6O0ecFolnXt8yF_c79G97p04Fb1LwfdlgrPZxshlLds3XPOmaq-q70PK4z_AbMpEDACupARRuNSeP-QZ2Wkjzo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79085863</pqid></control><display><type>article</type><title>Clinical trial of clonidine hydrochloride as an antisecretory agent in cholera</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>Alma/SFX Local Collection</source><creator>Rabbani, G.H. ; Butler, Thomas ; Patte, Didier ; Abud, Rodney L.</creator><creatorcontrib>Rabbani, G.H. ; Butler, Thomas ; Patte, Didier ; Abud, Rodney L.</creatorcontrib><description>Clonidine hydrochloride (an α2-adrenoceptor agonist) was tested for antisecretory effects in patients with cholera in a randomized controlled trial. Nineteen adults with diarrhea due to Vibrio cholerae were treated with clonidine (0.9 mg/24 h orally for 72 h) and 18 served as controls. During the first 24 h of treatment and for 24 h afterwards, the mean ± SD concentrations of sodium (in millimoles per liter) in the stools of clonidine-treated patients were 120.6 ± 10.9 and 112.3 ± 11.9, which were significantly lower than 135.5 ± 17.1 and 125.0 ± 16.4 in the controls (p < 0.01). Stool chloride concentrations (in millimoles per liter) were also significantly less in the clonidine group during the same periods: 82.1 ± 16.8 and 62.4 ± 19.4 vs. 92.1 ± 18.3 and 78.0 ± 23.0, respectively (p < 0.05). Concentrations of potassium but not bicarbonate were also significantly reduced in the stools of clonidine-treated patients (p < 0.05). However, there were no significant differences in the mean ± SD stool volumes (in liters) between the clonidine and the control group in any of the six 12-h periods after treatment or in the cumulative volumes in 72 h (24.2 ± 10.6 and 22.9 ± 8.3, respectively). We conclude that clonidine causes modest reduction of stool electrolyte loss but does not significantly reduce fecal fluid loss in patients with cholera.</description><identifier>ISSN: 0016-5085</identifier><identifier>EISSN: 1528-0012</identifier><identifier>DOI: 10.1016/0016-5085(89)90067-X</identifier><identifier>PMID: 2663610</identifier><identifier>CODEN: GASTAB</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adult ; Antidiarrheals ; Biological and medical sciences ; Cholera - drug therapy ; Clinical Trials as Topic ; Clonidine - pharmacology ; Clonidine - therapeutic use ; Digestive system ; Feces - analysis ; Female ; Humans ; Male ; Medical sciences ; Pharmacology. Drug treatments ; Random Allocation ; Water-Electrolyte Balance - drug effects</subject><ispartof>Gastroenterology (New York, N.Y. 1943), 1989-08, Vol.97 (2), p.321-325</ispartof><rights>1989</rights><rights>1991 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c433t-5d700579cca54c0e35a8f2ee8128b5f0d96cf6fc117f6faec5c63d08cf929d693</citedby><cites>FETCH-LOGICAL-c433t-5d700579cca54c0e35a8f2ee8128b5f0d96cf6fc117f6faec5c63d08cf929d693</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/001650858990067X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19722218$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2663610$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rabbani, G.H.</creatorcontrib><creatorcontrib>Butler, Thomas</creatorcontrib><creatorcontrib>Patte, Didier</creatorcontrib><creatorcontrib>Abud, Rodney L.</creatorcontrib><title>Clinical trial of clonidine hydrochloride as an antisecretory agent in cholera</title><title>Gastroenterology (New York, N.Y. 1943)</title><addtitle>Gastroenterology</addtitle><description>Clonidine hydrochloride (an α2-adrenoceptor agonist) was tested for antisecretory effects in patients with cholera in a randomized controlled trial. Nineteen adults with diarrhea due to Vibrio cholerae were treated with clonidine (0.9 mg/24 h orally for 72 h) and 18 served as controls. During the first 24 h of treatment and for 24 h afterwards, the mean ± SD concentrations of sodium (in millimoles per liter) in the stools of clonidine-treated patients were 120.6 ± 10.9 and 112.3 ± 11.9, which were significantly lower than 135.5 ± 17.1 and 125.0 ± 16.4 in the controls (p < 0.01). Stool chloride concentrations (in millimoles per liter) were also significantly less in the clonidine group during the same periods: 82.1 ± 16.8 and 62.4 ± 19.4 vs. 92.1 ± 18.3 and 78.0 ± 23.0, respectively (p < 0.05). Concentrations of potassium but not bicarbonate were also significantly reduced in the stools of clonidine-treated patients (p < 0.05). However, there were no significant differences in the mean ± SD stool volumes (in liters) between the clonidine and the control group in any of the six 12-h periods after treatment or in the cumulative volumes in 72 h (24.2 ± 10.6 and 22.9 ± 8.3, respectively). We conclude that clonidine causes modest reduction of stool electrolyte loss but does not significantly reduce fecal fluid loss in patients with cholera.</description><subject>Adult</subject><subject>Antidiarrheals</subject><subject>Biological and medical sciences</subject><subject>Cholera - drug therapy</subject><subject>Clinical Trials as Topic</subject><subject>Clonidine - pharmacology</subject><subject>Clonidine - therapeutic use</subject><subject>Digestive system</subject><subject>Feces - analysis</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Random Allocation</subject><subject>Water-Electrolyte Balance - drug effects</subject><issn>0016-5085</issn><issn>1528-0012</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1989</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEFrGzEQhUVocZw0_yCFvTSkh20lraWVLoFgkqZg2ksLvgllNKoV1lIirQv-95Fjk9wCw8zhvXnMfIScM_qNUSa_09paQZW4VPqrplT27fKITJngqq0a_0Cmr5ZjclLKA6VUd4pNyIRL2UlGp-TXfAgxgB2aMYfak29gSDG4ELFZbV1OsBpSDg4bWxoba42hIGQcU9429h_GsQmxgVUaMNtP5KO3Q8Gzwzwlf29v_szv2sXvHz_n14sWZl03tsL1lIpeA1gxA4qdsMpzRMW4uheeOi3BSw-M9XVYBAGyc1SB11w7qbtTcrHPfczpaYNlNOtQAIfBRkybYnpdn1ayq8bZ3gg5lZLRm8cc1jZvDaNmh9HsGJkdI6O0ecFolnXt8yF_c79G97p04Fb1LwfdlgrPZxshlLds3XPOmaq-q70PK4z_AbMpEDACupARRuNSeP-QZ2Wkjzo</recordid><startdate>19890801</startdate><enddate>19890801</enddate><creator>Rabbani, G.H.</creator><creator>Butler, Thomas</creator><creator>Patte, Didier</creator><creator>Abud, Rodney L.</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19890801</creationdate><title>Clinical trial of clonidine hydrochloride as an antisecretory agent in cholera</title><author>Rabbani, G.H. ; Butler, Thomas ; Patte, Didier ; Abud, Rodney L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c433t-5d700579cca54c0e35a8f2ee8128b5f0d96cf6fc117f6faec5c63d08cf929d693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1989</creationdate><topic>Adult</topic><topic>Antidiarrheals</topic><topic>Biological and medical sciences</topic><topic>Cholera - drug therapy</topic><topic>Clinical Trials as Topic</topic><topic>Clonidine - pharmacology</topic><topic>Clonidine - therapeutic use</topic><topic>Digestive system</topic><topic>Feces - analysis</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Random Allocation</topic><topic>Water-Electrolyte Balance - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rabbani, G.H.</creatorcontrib><creatorcontrib>Butler, Thomas</creatorcontrib><creatorcontrib>Patte, Didier</creatorcontrib><creatorcontrib>Abud, Rodney L.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gastroenterology (New York, N.Y. 1943)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rabbani, G.H.</au><au>Butler, Thomas</au><au>Patte, Didier</au><au>Abud, Rodney L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical trial of clonidine hydrochloride as an antisecretory agent in cholera</atitle><jtitle>Gastroenterology (New York, N.Y. 1943)</jtitle><addtitle>Gastroenterology</addtitle><date>1989-08-01</date><risdate>1989</risdate><volume>97</volume><issue>2</issue><spage>321</spage><epage>325</epage><pages>321-325</pages><issn>0016-5085</issn><eissn>1528-0012</eissn><coden>GASTAB</coden><abstract>Clonidine hydrochloride (an α2-adrenoceptor agonist) was tested for antisecretory effects in patients with cholera in a randomized controlled trial. Nineteen adults with diarrhea due to Vibrio cholerae were treated with clonidine (0.9 mg/24 h orally for 72 h) and 18 served as controls. During the first 24 h of treatment and for 24 h afterwards, the mean ± SD concentrations of sodium (in millimoles per liter) in the stools of clonidine-treated patients were 120.6 ± 10.9 and 112.3 ± 11.9, which were significantly lower than 135.5 ± 17.1 and 125.0 ± 16.4 in the controls (p < 0.01). Stool chloride concentrations (in millimoles per liter) were also significantly less in the clonidine group during the same periods: 82.1 ± 16.8 and 62.4 ± 19.4 vs. 92.1 ± 18.3 and 78.0 ± 23.0, respectively (p < 0.05). Concentrations of potassium but not bicarbonate were also significantly reduced in the stools of clonidine-treated patients (p < 0.05). However, there were no significant differences in the mean ± SD stool volumes (in liters) between the clonidine and the control group in any of the six 12-h periods after treatment or in the cumulative volumes in 72 h (24.2 ± 10.6 and 22.9 ± 8.3, respectively). We conclude that clonidine causes modest reduction of stool electrolyte loss but does not significantly reduce fecal fluid loss in patients with cholera.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>2663610</pmid><doi>10.1016/0016-5085(89)90067-X</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0016-5085 |
ispartof | Gastroenterology (New York, N.Y. 1943), 1989-08, Vol.97 (2), p.321-325 |
issn | 0016-5085 1528-0012 |
language | eng |
recordid | cdi_proquest_miscellaneous_79085863 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete; Alma/SFX Local Collection |
subjects | Adult Antidiarrheals Biological and medical sciences Cholera - drug therapy Clinical Trials as Topic Clonidine - pharmacology Clonidine - therapeutic use Digestive system Feces - analysis Female Humans Male Medical sciences Pharmacology. Drug treatments Random Allocation Water-Electrolyte Balance - drug effects |
title | Clinical trial of clonidine hydrochloride as an antisecretory agent in cholera |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T10%3A42%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20trial%20of%20clonidine%20hydrochloride%20as%20an%20antisecretory%20agent%20in%20cholera&rft.jtitle=Gastroenterology%20(New%20York,%20N.Y.%201943)&rft.au=Rabbani,%20G.H.&rft.date=1989-08-01&rft.volume=97&rft.issue=2&rft.spage=321&rft.epage=325&rft.pages=321-325&rft.issn=0016-5085&rft.eissn=1528-0012&rft.coden=GASTAB&rft_id=info:doi/10.1016/0016-5085(89)90067-X&rft_dat=%3Cproquest_cross%3E79085863%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79085863&rft_id=info:pmid/2663610&rft_els_id=001650858990067X&rfr_iscdi=true |